Regeneron Pharmaceuticals' Operating Income fell 12.95% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year decrease of 7.18%. This contributed to the annual value of $4.0 billion for FY2024, which is 1.39% down from last year.
Per Regeneron Pharmaceuticals' latest filing, its Operating Income stood at $1.0 billion for Q3 2025, which was down 4.88% from $1.1 billion recorded in Q2 2025.
In the past 5 years, Regeneron Pharmaceuticals' Operating Income ranged from a high of $3.3 billion in Q2 2021 and a low of $591.7 million during Q1 2025.
Over the past 3 years, Regeneron Pharmaceuticals' median Operating Income value was $1.0 billion (recorded in 2023), while the average stood at $976.0 million.
Its Operating Income has fluctuated over the past 5 years, first spiked by 409.93% in 2021, then slumped by 66.84% in 2022.
Over the past 5 years, Regeneron Pharmaceuticals' Operating Income (Quarterly) stood at $2.6 billion in 2021, then crashed by 56.56% to $1.1 billion in 2022, then dropped by 15.16% to $972.9 million in 2023, then climbed by 1.78% to $990.2 million in 2024, then dropped by 12.95% to $1.0 billion in 2025.
Its last three reported values are $1.0 billion in Q3 2025, $1.1 billion for Q2 2025, and $591.7 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value